RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(31/32): 1577-1580
DOI: 10.1055/s-0031-1281556
DOI: 10.1055/s-0031-1281556
Hämatologie und Onkologie | Commentary
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York
Akute myeloische Leukämie: von der risikoadaptierten zur Genotyp-spezifischen Therapie
Acute myeloid leukemia: from risk-adapted to genotype-specific therapyWeitere Informationen
Publikationsverlauf
Publikationsdatum:
01. August 2011 (online)
![](https://www.thieme-connect.de/media/dmw/20113132/lookinside/thumbnails/10.1055-s-0031-1281556-1.jpg)
Schlüsselwörter
akute myeloische Leukämie - Mutationen
Keywords
acute myeloid leukemia - mutations
Literatur
- 1 Arber D A, Vardiman J W, Brunning R D. et al .Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow S H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.. Geneva: WHO; 2008
- 2 Becker H, Marcucci G, Maharry K. et al . Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures. J Clin Oncol. 2010; 28 596-604
- 3 Burnett A K, Hills R K, Milligan D. et al . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011; 29 369-377
- 4 Delhommeau F, Dupont S, Della Valle V. et al . Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360 2289-2301
- 5 Döhner H, Estey E H, Amadori S. et al . Diagnosis and management of acute myeloid leukemia in adults. Blood. 2010; 115 453-474
- 6 Figueroa M E, Abdel-Wahab O, Lu C. et al . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18 553-567
- 7 Juliusson G, Antunovic P, Derolf A. et al . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113 4179-4187
- 8 Koreth J, Schlenk R, Kopecky K J. et al . Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission. JAMA. 2009; 301 2349-2361
- 9 Ley T J, Ding L, Walter M J. et al . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363 2424-2433
- 10 Löwenberg B, Ossenkoppele G J, van Putten W. et al . High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361 1235-1248
- 11 Mayer R J, Davis R B. et al . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331 896-903
- 12 Paschka P, Schlenk R F, Gaidzik V I. et al . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010; 28 3636-3643
- 13 Schlenk R F, Döhner K, Kneba M. et al . Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with Acute Myeloid Leukemia. Haematologica. 2009; 94 54-60
- 14 Schlenk R F, Döhner K, Krauter J. et al . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358 1909-1918
- 15 Schlenk R F, Döhner K, Mack S. et al . Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010; 28 4642-4648
- 16 Schlenk R F, Ganser A, Döhner K. Prognostic and predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. ASCO Educational Book. http://www.asco.org 2010; 228-232
- 17 Stone R M, Fischer T, Paquette R. et al . A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia. Blood. 2009; 114 634 (Abstract)
- 18 Taskesen E, Bullinger L, Corbacioglu A. et al . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients. Blood. 2011; 117 2469-2475
PD Dr. Richard F. Schlenk
Klinik für Innere Medizin III
Universitätsklinikum
Ulm
Albert-Einstein-Allee 23
89081 Ulm
Telefon: 0731/500-45900
Fax: 0731/500-45905
eMail: richard.schlenk@uniklinik-ulm.de